Antiangiogenic activity of Andrographis paniculata extract and andrographolide

International Immunopharmacology

Volumn 7, Issue 2, 2007, Pages 211-221

  Sheeja, K ^a   Guruvayoorappan, C ^a   Kuttan, G ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Andrographis paniculata; Angiogenesis; Nitric oxide; Proinflammatory cytokines; VEGF

Indexed keywords

ANDROGRAPHIS PANICULATA EXTRACT; ANDROGRAPHOLIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; NITRIC OXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; VASCULAR RING;

ANDROGRAPHIS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AORTA, THORACIC; CELL LINE, TUMOR; CYTOKINES; DITERPENES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845936572     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.10.002     Document Type: Article

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 1182-1186
2. Hartford A.C., Gohongi T., Fukumura D., and Jain R.K. Irriadiation of primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distant site: potential role of host-tumor interaction. Cancer Res 60 (2000) 2128-2131
3. Risau W. Mechanisms of angiogenesis. Nature (Lond) 386 (1997) 671-674
4. Walsh D.A., and Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 31 (2001) 147-153
5. Distler J.H.W., Hirth A., Kurowska-Stolarska M., Gay R.E., Gay S., and Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47 (2003) 149-161
6. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of HIF system. Nat Med 9 (2003) 677-684
7. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
8. Reinmuth N., Liu W., Jung Y.D., Ahmad S.A., Shaheen R.M., Fan F., et al. Induction of VEGF in perivascular cell defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15 (2001) 1239-1241
9. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
10. Schietroma C., Cianfarani F., Lacal P.M., Odorisio T., Orecchia A., Kanitakis J., et al. Vascular endothelial growth factor-c expression correlates with lymph node localization of human melanoma metastases. Cancer 98 (2003) 789-797
11. Ballou S.P., and Kushner I. Laboratory evaluation of inflammation. In: Kelley W.N., Harris Jr. E.D., Ruddy S., and Sledge C.B. (Eds). Text book of rheumatology (2000), WB Saunders Co., Philadelphia 697-703
12. Waterston A., and Bower M. TNF and cancer: good or bad. Cancer Ther 2 (2004) 131-148
13. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
14. Chen Z., Malhotra P.S., Thomas G.R., Ondrey F.G., Duffey D.C., Smith C.W., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 (1999) 1369-1379
15. Bloomston M., Shafii B.S.A., Zervos E.E., and Rosemurgy A.S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis and inhibits angiogenesis. J Surg Res 102 (2002) 39-44
16. Josko J., and Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10 (2004) 89-98
17. Buttery L.D.K., Springall D.R., Andrade S.P., Riveros-Moreno V., Hart I., Piper P.J., et al. Induction of nitric oxide synthase in the neovasculature of experimental tumours in mice. J Pathol 171 (1993) 311-319
18. Griffioen A.W., and Molema G. Angiogenesis: potentials for pharmacologic intervention in treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol Rev 52 (2000) 237-268
19. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
20. Yance D.R., and Sagar S.M. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther 5 (2006) 9-29
21. Leyon P.V., and Kuttan G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumor specific angiogenesis. J Exp Clin Cancer Res 22 (2003) 77-83
22. Sunila E.S., and Kuttan G. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice. Int Immunopharmacol 6 (2006) 733-741
23. Zhang X.F., and Tan B.K. Anti diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats. Acta Pharmacol Sin 21 (2000) 1157-1164
24. Zhao H.Y., and Frang W.Y. Antithrombotic effect of Andrographis paniculata nees in preventing myocardial infraction. Chin Med J (Engl) 104 (1991) 770-775
25. Sheeja K., Shihab P.K., and Kuttan G. Antioxidant and Anti inflammatory activities of the plant Andrographis paniculata Nees. Immunopharmacol Immunotoxicol 28 (2006) 129-140
26. Visen P.K., Shukla B., Patnaik G.K., and Dhawan B.N. Andrographolide protects rat hepatocytes against paracetamol-induced damage. J Ethnopharmacol 40 (1993) 131-136
27. Calabrese C., Berman S.H., Babish J.G., Ma X., Shinto L., Dorr M., et al. A phase I trail of andrographolide in HIV positive patients and normal volunteers. Phytother Res 14 (2000) 333-338
28. Hidalgo M.A., Romero A., Figueroa J., Cortes P., Concha H.I., Hancke J.L., et al. Andrographolide interferes with binding of nuclear factor-kB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 144 (2005) 680-686
29. Handa S.S., and Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. Indian J Med Res 92 (1990) 276-283
30. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., and Tannenbaum S.R. Analysis of nitrate nitrite and [15N] nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
31. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L., et al. Preferential enhancement of tumor radioresponse by Cycloxygenase-2 inhibition. Cancer Res 60 (2000) 1326-1331
32. Ng S.S., Gutschow M., Weiss M., Hauschildt S., Teubert U., Hecker T.K., et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63 (2003) 3189-3194
33. Longo R., Sarmiento R., Fanelli M., Capaccettii B., Gattuso D., and Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5 (2002) 237-256
34. Indraccolo S. Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther 4 (2004) 297-308
35. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., and Winkler J.D. The codependence of angiogenesis and chronic inflammation. FASEB J 11 (1997) 457-465
36. Polverini P.J. Role of the macrophage in angiogenesis-dependent disease. In: Goldberg I.D., Rosen E.M., and Birkhauser B. (Eds). Regulation of angiogenesis (1997) 11-28
37. Wang J.M., Deng X., Gong W., and Su S. Chemokine and their role in tumor growth and metastasis. J Immunol Methods 220 (1998) 1-17
38. Spechler S.J. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 117 (1999) 218-228
39. Kleer C.G., van Golen K.L., and Merajver S.D. Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2 (2000) 423-429
40. Shirakawa K.H., Tsuda H., Heike Y., Kato K., Asada R., Inomata M., et al. Absence of endothelial cell necrosis and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61 (2001) 445-451
41. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355 (2000) 248-250
42. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
43. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Naemondo M., et al. Proinflammatory cytokines IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 169 (2002) 469-475
44. Shin K.Y., Moon H.S., Park H.Y., Lee T.Y., Woo Y.N., Kim H.J., et al. Effects of tumor necrosis factor-alpha and interferon-gamma on expression of matrix metalloproteinase-2 and -9, in human bladder cancer cells. Cancer Lett 159 (2000) 127-134
45. +exchanger in human endothelial cells activated by granulocyte, granulocyte-macrophage-colony stimulating factor. Evidence for a role in proliferation and migration. J Biol Chem 264 (1989) 18284-18287
46. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., and De Bruijn E.A. Vascular endothelial growth factors and angiogenesis. Pharmacol Rev 56 (2004) 549-580
47. Neville M.E., Robb R.J., and Popescu M.C. In situ vaccination against a non-immunogenic tumor using intratumoral injection of liposomal interleukin 2. Cytokine 16 (2001) 239-250
48. Hajitou A., Sounni N.E., Devy L., Grignet-Debrus C., Lewalle J.M., Li H., et al. Down regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect in vivo mammary tumor growth and angiogenesis. Cancer Res 61 (2001) 3450-3457